Your browser doesn't support javascript.
loading
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat, Veena; Raman, Ayush T; Landers, Sharon M; Tang, Ming; Schulz, Jonathan; Terranova, Christopher; Landry, Jace P; Bhalla, Angela D; Beird, Hannah C; Wu, Chia-Chin; Jiang, Yingda; Mao, Xizeng; Lazcano, Rossana; Gite, Swati; Ingram, Davis R; Yi, Min; Zhang, Jianhua; Keung, Emily Z; Scally, Christopher P; Roland, Christina L; Hunt, Kelly K; Feig, Barry W; Futreal, P Andrew; Hwu, Patrick; Wang, Wei-Lien; Lazar, Alexander J; Slopis, John M; Wilson-Robles, Heather; Wiener, Dominique J; McCutcheon, Ian E; Wustefeld-Janssens, Brandan; Rai, Kunal; Torres, Keila E.
Afiliación
  • Kochat V; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Raman AT; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Landers SM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tang M; Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, TX, USA.
  • Schulz J; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Terranova C; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Landry JP; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bhalla AD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Beird HC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wu CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jiang Y; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mao X; Louisiana State University School of Medicine, New Orleans, LA, USA.
  • Lazcano R; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gite S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ingram DR; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yi M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Keung EZ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Scally CP; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Roland CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hunt KK; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feig BW; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang WL; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lazar AJ; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Slopis JM; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wilson-Robles H; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wiener DJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McCutcheon IE; Department of Melanoma Medical Oncology and Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wustefeld-Janssens B; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Rai K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Torres KE; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Acta Neuropathol ; 142(3): 565-590, 2021 09.
Article en En | MEDLINE | ID: mdl-34283254
ABSTRACT
Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that frequently harbor genetic alterations in polycomb repressor complex 2 (PRC2) components-SUZ12 and EED. Here, we show that PRC2 loss confers a dedifferentiated early neural-crest phenotype which is exclusive to PRC2-mutant MPNSTs and not a feature of neurofibromas. Neural crest phenotype in PRC2 mutant MPNSTs was validated via cross-species comparative analysis using spontaneous and transgenic MPNST models. Systematic chromatin state profiling of the MPNST cells showed extensive epigenomic reprogramming or chromatin states associated with PRC2 loss and identified gains of active enhancer states/super-enhancers on early neural crest regulators in PRC2-mutant conditions around genomic loci that harbored repressed/poised states in PRC2-WT MPNST cells. Consistently, inverse correlation between H3K27me3 loss and H3K27Ac gain was noted in MPNSTs. Epigenetic editing experiments established functional roles for enhancer gains on DLX5-a key regulator of neural crest phenotype. Consistently, blockade of enhancer activity by bromodomain inhibitors specifically suppressed this neural crest phenotype and tumor burden in PRC2-mutant PDXs. Together, these findings reveal accumulation of dedifferentiated neural crest like state in PRC2-mutant MPNSTs that can be targeted by enhancer blockade.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Nervioso Periférico / Neoplasias de la Vaina del Nervio / Complejo Represivo Polycomb 2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Acta Neuropathol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Nervioso Periférico / Neoplasias de la Vaina del Nervio / Complejo Represivo Polycomb 2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Acta Neuropathol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...